Literature DB >> 31668594

Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.

Michelle M Mielke1, Jeremy A Syrjanen2, Kaj Blennow3, Henrik Zetterberg4, Ingmar Skoog5, Prashanthi Vemuri6, Mary M Machulda7, Jonathan Graff-Radford8, David S Knopman8, Clifford R Jack6, Ronald C Petersen9, Silke Kern10.   

Abstract

INTRODUCTION: Three cerebrospinal fluid (CSF) markers of neurodegeneration (N) (neurofilament light [NfL], total-tau [T-tau], and neurogranin [Ng]) have been proposed under the AT(N) scheme of the National Institute on Aging-Alzheimer's Association Research Framework.
METHODS: We examined, in a community-based population (N = 777, aged 50-95) (1) what variables were associated with each of the CSF (N) markers, and (2) whether the variables associated with each marker differed by increased brain amyloid. CSF T-tau was measured with an automated electrochemiluminescence Elecsys immunoassay; NfL and Ng were measured with in-house enzyme-linked immunosorbent assays.
RESULTS: Multiple variables were differentially associated with CSF NfL and T-tau levels, but not Ng. Most associations were attenuated after adjustment for age and sex. T-tau had the strongest association with cognition in the presence of amyloidosis, followed by Ng. Variables associations with NfL did not differ by amyloid status. DISCUSSION: Understanding factors that influence CSF (N) markers will assist in the interpretation and utility of these markers in clinical practice.
Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebrospinal fluid; Community-based population; Neurodegeneration; Neurofilament light chain; Neurogranin; Total-tau; Vascular factors

Mesh:

Substances:

Year:  2019        PMID: 31668594      PMCID: PMC6874755          DOI: 10.1016/j.jalz.2019.07.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  30 in total

1.  Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia.

Authors:  Yin Ting Cheung; Raja B Khan; Wei Liu; Tara M Brinkman; Michelle N Edelmann; Wilburn E Reddick; Deqing Pei; Angela Panoskaltsis-Mortari; Deokumar Srivastava; Cheng Cheng; Leslie L Robison; Melissa M Hudson; Ching-Hon Pui; Kevin R Krull
Journal:  JAMA Oncol       Date:  2018-07-12       Impact factor: 31.777

2.  Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.

Authors:  Isabelle Bos; Stephanie Vos; Frans Verhey; Philip Scheltens; Charlotte Teunissen; Sebastiaan Engelborghs; Kristel Sleegers; Giovanni Frisoni; Olivier Blin; Jill C Richardson; Régis Bordet; Magda Tsolaki; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Alberto Lleó; Peter Johannsen; Yvonne Freund-Levi; Lutz Frölich; Rik Vandenberghe; Sarah Westwood; Valerija Dobricic; Frederik Barkhof; Cristina Legido-Quigley; Lars Bertram; Simon Lovestone; Johannes Streffer; Ulf Andreasson; Kaj Blennow; Henrik Zetterberg; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2019-03-08       Impact factor: 21.566

3.  Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.

Authors:  Silke Kern; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Margda Waern; Clinton E Hagen; Argonde C van Harten; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2019-02-01       Impact factor: 18.302

4.  Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.

Authors:  Joana B Pereira; Eric Westman; Oskar Hansson
Journal:  Neurobiol Aging       Date:  2017-06-17       Impact factor: 4.673

5.  Neurocognitive Sequelae in Adult Childhood Leukemia Survivors Related to Levels of Phosphorylated Tau.

Authors:  Iris Elens; Sabine Deprez; Marina Danckaerts; Patricia Bijttebier; Veerle Labarque; Anne Uyttebroeck; Stefaan Van Gool; Rudi D'Hooge; Jurgen Lemiere
Journal:  J Natl Cancer Inst       Date:  2017-07-01       Impact factor: 13.506

6.  Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging.

Authors:  Rodolfo Savica; Alexandra M V Wennberg; Clinton Hagen; Kelly Edwards; Rosebud O Roberts; John H Hollman; David S Knopman; Bradley F Boeve; Mary M Machulda; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 7.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

Review 8.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

9.  Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures.

Authors:  Michelle M Mielke; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Prashanthi Vemuri; Ingmar Skoog; Mary M Machulda; Walter K Kremers; David S Knopman; Clifford Jack; Ronald C Petersen; Silke Kern
Journal:  Neurology       Date:  2019-06-10       Impact factor: 9.910

10.  A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.

Authors:  Lorenzo Gaetani; Kina Höglund; Lucilla Parnetti; Fani Pujol-Calderon; Bruno Becker; Paolo Eusebi; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2018-01-23       Impact factor: 6.982

View more
  12 in total

Review 1.  Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers.

Authors:  Michelle M Mielke
Journal:  J Appl Lab Med       Date:  2020-01-01

2.  Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.

Authors:  Michelle M Mielke; Neelum T Aggarwal; Clara Vila-Castelar; Puja Agarwal; Eider M Arenaza-Urquijo; Benjamin Brett; Anna Brugulat-Serrat; Lyndsey E DuBose; Willem S Eikelboom; Jason Flatt; Nancy S Foldi; Sanne Franzen; Paola Gilsanz; Wei Li; Alison J McManus; Debora Melo van Lent; Sadaf Arefi Milani; C Elizabeth Shaaban; Shana D Stites; Erin Sundermann; Vidyani Suryadevara; Jean-Francoise Trani; Arlener D Turner; Jet M J Vonk; Yakeel T Quiroz; Ganesh M Babulal
Journal:  Alzheimers Dement       Date:  2022-04-08       Impact factor: 16.655

3.  Association of Neurofilament Light With the Development and Severity of Parkinson Disease.

Authors:  Shannon Halloway; Pankaja Desai; Todd Beck; Neelum Aggarwal; Puja Agarwal; Denis Evans; Kumar B Rajan
Journal:  Neurology       Date:  2022-04-13       Impact factor: 11.800

4.  Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.

Authors:  Vijay K Ramanan; Michael G Heckman; Timothy G Lesnick; Scott A Przybelski; Elliot J Cahn; Matthew L Kosel; Melissa E Murray; Michelle M Mielke; Hugo Botha; Jonathan Graff-Radford; David T Jones; Val J Lowe; Mary M Machulda; Clifford R Jack; David S Knopman; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri
Journal:  Acta Neuropathol       Date:  2022-04-12       Impact factor: 15.887

5.  P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.

Authors:  Michelle R Campbell; Susan Ashrafzadeh-Kian; Ronald C Petersen; Michelle M Mielke; Jeremy A Syrjanen; Argonde C van Harten; Val J Lowe; Clifford R Jack; Joshua A Bornhorst; Alicia Algeciras-Schimnich
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-18

6.  Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.

Authors:  Michelle M Mielke; Scott A Przybelski; Timothy G Lesnick; Silke Kern; Henrik Zetterberg; Kaj Blennow; David S Knopman; Jonathan Graff-Radford; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri
Journal:  Alzheimers Dement       Date:  2021-03-04       Impact factor: 16.655

7.  Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults.

Authors:  Lingxiao He; Philipe de Souto Barreto; Geetika Aggarwal; Andrew D Nguyen; John E Morley; Yan Li; Randall J Bateman; Bruno Vellas
Journal:  Alzheimers Res Ther       Date:  2020-10-08       Impact factor: 6.982

8.  Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia.

Authors:  Christoph Kessler; Lina M Serna-Higuita; Tim W Rattay; Walter Maetzler; Isabel Wurster; Stefanie Hayer; Carlo Wilke; Holger Hengel; Jennifer Reichbauer; Marcel Armbruster; Ludger Schöls; Peter Martus; Rebecca Schüle
Journal:  Ann Clin Transl Neurol       Date:  2021-04-05       Impact factor: 4.511

9.  Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.

Authors:  Michelle M Mielke; Jeremiah A Aakre; Alicia Algeciras-Schimnich; Nicholas K Proctor; Mary M Machulda; Udo Eichenlaub; David S Knopman; Prashanthi Vemuri; Jonathan Graff-Radford; Clifford R Jack; Ronald C Petersen; Jeffrey L Dage
Journal:  Alzheimers Dement       Date:  2021-07-26       Impact factor: 16.655

Review 10.  Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer's Disease.

Authors:  Bin Zhou; Masanori Fukushima
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.